This disclosure provides compositions, devices, systems, and methods that reduce the likelihood, amount, or level of cellular deposition (and associated blockage and/or failure) of implantable medical devices, such as central nervous system implants. Embodiments involve use of inhibitor(s) of one or more of TLR-4, TNF-, IL-1, or IL-6, for instance, to prevent, reduce, or reverse activation of astrocyte and/or glia cells, and/or to prevent, reduce, or reverse attachment of such cells to the surface of a medical device in contact with a biological fluid, such as cerebrospinal fluid.

Improvements in a dental/prosthetic implant is disclosed. The implant includes interior and exterior threaded surfaces. The use of both interior and exterior expanding threaded surfaces for integrations of the insert and a prosthetic with the same implant. The implant is immediately usable under load and promotes rapid integration with bone growth. The expanded insert essentially makes contact with the tapped bone surfaces where loads can be immediately applied so a person can utilize the prosthetic implant. The implant can further include security devices GPS, ID with medical records making removal of the implant difficult to extract. A cushioning member may be further integrated. The implant/abutment can include a surface with a plurality of contacts with sufficient gold contact points to attach residual nerve endings, during implanting surgery to provide nerve identification, send, receive, target so as to exploit proprioceptive memory or retraining.

A system and method for treating neural lesions is disclosed. The inventive method comprises determining the location of a neural lesion in a patient and applying a selected modality to a dermatomal region on the patient to compensate for the existence of the neural lesion. The selected modality includes the implementation of a method or device to activate any number of receptors located in the skin of the patient. The modality implemented in the correct dermatomal region initiates a somatosensory signal to the brain which responds with a corresponding motor signal to the affected area. Proper implementation of the selected modality supports neuroplasticity and neurogenesis to create a permanent solution to overcome the neural lesion.

The present disclosure relates to an ICM system and a probe assembly. The probe assembly includes a catheter with a front end configured to insert into the skull of a monitored person; and an FPC-sensor integrated probe sealing arranged within the catheter, the FPC-sensor integrated probe comprises an absolute pressure sensor chip; a temperature sensor chip; a signal chain chip; and a strip-shaped FPC; the absolute pressure sensor chip, the temperature sensor chip and the signal chain chip are COF encapsulated in bare chips or SMT encapsulated onto the FPC; or alternatively are COB encapsulated in bare chips or SMT encapsulated onto a rigid micro circuit board which is integrated with the FPC; the absolute pressure sensor chip, the temperature sensor chip and the signal chain chip are positioned on the FPC such that their operating ambient temperatures are substantially the same.

Methods and systems useful for detecting neurological disorders and for measuring general cognitive performance, in particular by measuring eye movements and/or pupil diameter during eye-movement tasks.

A method for creating calibration data for processing accelerated measurement data of an object to be examined using a magnetic resonance system. The method includes recording measurement data sets using an acquisition acceleration method, recording calibration data sets, and determining processed measurement data sets from the accelerated measurement data sets using the calibration data sets so that effects of the acquisition acceleration method used are eliminated in the processed measurement data sets. The recording of the calibration data sets includes an application of at least one attenuation method for attenuating signals causing phase errors.

The invention provides a quantum dot (QD) modified optical fiber-based biosensor which characterizes matrix metalloproteinase (MMP) enzyme activity at pain signaling sites in the central nervous system (CNS) in vivo. Related systems and peptide biomarker screening methods are also provided.

Systems and methods for providing quantitative measurements of global glymphatic flow of cerebrospinal fluid (CSF) using magnetic resonance imaging (MRI) are described. In general, images are obtained from a subject using flow-sensitive MRI techniques that are designed to be particularly sensitive to the glymphatic flow of CSF. Measures of glymphatic flow can be obtained while the subject is in an awake state and again while the subject is in a sleep state. Based on these two measurements, a biomarker that indicates a neurological state or disease can be generated.

One aspect of the present disclosure can include a method for implanting a neural electrode in a fascicle including a target nerve. One step of the method can include inserting a microwire assembly into the fascicle. The microwire assembly can comprise a microwire body that is coiled around a needle introducer. Next, a portion of the microwire body can be uncoiled from around the needle introducer so that a distal end of the microwire body retains a spiral-shaped configuration. The needle introducer can then be withdrawn so that the spiral-shaped distal end of the microwire body remains implanted in the fascicle.

Systems and methods for providing quantitative measurements of global glymphatic flow of cerebrospinal fluid (CSF) using magnetic resonance imaging (MRI) are described. In general, images are obtained from a subject using flow-sensitive MRI techniques that are designed to be particularly sensitive to the glymphatic flow of CSF. Measures of glymphatic flow can be obtained while the subject is in an awake state and again while the subject is in a sleep state. Based on these two measurements, a biomarker that indicates a neurological state or disease can be generated.